camptothecin has been researched along with gdc 0449 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendell, JC; Berlin, J; Bray, GL; Firdaus, I; Gore, I; Graham, RA; Hart, LL; Hermann, RC; Low, JA; Mackey, HM; Mulcahy, MF; Yauch, RL; Zalupski, MM | 1 |
| Liu, X; Lu, Z; Miao, Y; Shen, Y; Sui, M; Tang, J; Wang, L; Wang, W; Zheng, M; Zhou, Q; Zhou, Z | 1 |
1 trial(s) available for camptothecin and gdc 0449
| Article | Year |
|---|---|
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Treatment Outcome | 2013 |
1 other study(ies) available for camptothecin and gdc 0449
| Article | Year |
|---|---|
Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance.
Topics: Anilides; Animals; Antineoplastic Agents; Camptothecin; Coculture Techniques; Drug Resistance, Neoplasm; Drug Synergism; Female; Fibroblasts; Hedgehog Proteins; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Pyridines; Rats, Sprague-Dawley; Signal Transduction | 2017 |